{"name":"Energenesis Biomedical Co., Ltd.","slug":"energenesis-biomedical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ENERGI-F703 GEL","genericName":"ENERGI-F703 GEL","slug":"energi-f703-gel","indication":"Chronic wounds and ulcers (diabetic foot ulcers, pressure ulcers, venous leg ulcers)","status":"phase_3"},{"name":"ENERGI-F701","genericName":"ENERGI-F701","slug":"energi-f701","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ENERGI-F703 GEL matched vehicle","genericName":"ENERGI-F703 GEL matched vehicle","slug":"energi-f703-gel-matched-vehicle","indication":"Wound healing and tissue repair (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"Regaine","genericName":"Regaine","slug":"regaine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ENERGI-F703 GEL","genericName":"ENERGI-F703 GEL","slug":"energi-f703-gel","phase":"phase_3","mechanism":"ENERGI-F703 is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery.","indications":["Chronic wounds and ulcers (diabetic foot ulcers, pressure ulcers, venous leg ulcers)"],"catalyst":""},{"name":"ENERGI-F703 GEL matched vehicle","genericName":"ENERGI-F703 GEL matched vehicle","slug":"energi-f703-gel-matched-vehicle","phase":"phase_3","mechanism":"ENERGI-F703 is a topical gel formulation designed to promote wound healing and tissue repair through enhanced cellular regeneration.","indications":["Wound healing and tissue repair (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"ENERGI-F701","genericName":"ENERGI-F701","slug":"energi-f701","phase":"phase_2","mechanism":"ENERGI-F701 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Regaine","genericName":"Regaine","slug":"regaine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQZEFqalBHaXJoQ2ljNm1qcHd5QVlzeEsxYmd6bmRUNnR6Y2Izejk1SUpGV2xCTzVLUlNPMlUyNlctTEQ0bmFYRXJvN3A5bmN2UnFfOU96cWJqLWswTVUwUjJjQWNvb1Z5Z3NmVk52ZEhuM1RrcWY2ZGdfYTlhY2NKVGxVdUNJcUhqV1dUWk1ucGVDUGEwajg1OENhS3lDLVh6aEVkSGhaRnY1VlA2QzMzdjJZYw?oc=5","date":"2025-08-23","type":"pipeline","source":"Contract Pharma","summary":"Energenesis Highlights Investigational Parkinson’s Disease Therapy - Contract Pharma","headline":"Energenesis Highlights Investigational Parkinson’s Disease Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSS0yM0NPRGx0dnBxdjFLbXJ0NEpZVDR3Zzd3VnZSVWY5NE5VODJHVzRUaU5USVhVS2MzaG5EMHNCTzRlVmR4b2w1NFJtenJTVnhLbFVYekR6VXJKVkZnY3FUSkxPa3ZZTVhGMlBwT09nYmpxLW8tYVpFZ0UzQmI4UXJUenlkd050cDJweXRSM3ZhTDAyYTI4WE5iZ2RodFdiUmdDRWE5aW5PRmVZdXVfSy10SUlNSTU4SVFvcnpLOXRPQ242eXRxcDlxOWt0eUlXRVE?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - PR Newswire","headline":"Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPRWYzMkNnbWZxc3RFUkFTZHNQNTZDSDJ1ZWdoZ05RWk0wVVBMd0RyZHFGQmFZSkNJNzZmcHduQUFnUFB5ZWZlNS1zeWlxN1lROHprdzFlRko4TjBENWhBRnFmX0E1RmJ2bnpTUWVtSTVJR3pDRnphQm00WHBMRVo2R2JPLTFKYjlZS09sOFl2NzlzdTJl?oc=5","date":"2024-11-05","type":"pipeline","source":"finance.yahoo.com","summary":"Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight - finance.yahoo.com","headline":"Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}